Form 8-K - Current report:
SEC Accession No. 0001104659-25-100468
Filing Date
2025-10-17
Accepted
2025-10-17 17:19:25
Documents
15
Period of Report
2025-10-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2528131d2_8k.htm   iXBRL 8-K 46208
2 EXHIBIT 4.1 tm2528131d2_ex4-1.htm EX-4.1 97143
3 EXHIBIT 10.1 tm2528131d2_ex10-1.htm EX-10.1 62898
4 EXHIBIT 99.1 tm2528131d2_ex99-1.htm EX-99.1 11745
  Complete submission text file 0001104659-25-100468.txt   440220

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA syn-20251016.xsd EX-101.SCH 3041
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20251016_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20251016_pre.xml EX-101.PRE 22377
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2528131d2_8k_htm.xml XML 3692
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 251401585
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)